EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Phenotypes, Treatment, and Outcomes of Rheumatic Immune–Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitors: A Rheumatologists‐Referred Multicenter German Registry Cohort

Klinische Phänotypen, Behandlung und Outcomes rheumatischer immunvermittelter Nebenwirkungen bei mit Immuncheckpoint-Inhibitoren behandelten Patient:innen: multizentrische deutsche Registerkohorte mit rheumatologischer Zuweisung

Didzis Gailis iD, Fabian T H Ullrich iD, Sophia Dombret, Marc Schmalzing iD, Rebecca Hasseli-Fräbel iD, Torsten Witte, Thea Thiele, Uta Kiltz iD, Mara Oleszowsky, Marcel Müller, Karolina Gente iD, Christof Specker und 3 weitere

ACR Open Rheumatology · 2026-09 · 8 (9)

DOI: 10.1002/acr2.90145 ↗

Auf einen Blick

In der deutschen ERIN-Registerkohorte waren rheumatische irAEs häufig moderat oder schwer und führten oft zu Glukokortikoiden, Behandlungseskalation und Abbruch der Immuncheckpoint-Inhibitoren.

Fragestellung

Beschreiben die Autor:innen klinische Phänotypen, Behandlung und Outcomes rheumatischer irAEs in einem nationalen Register?

Methode

Multizentrische beobachtende Registerstudie des deutschen ERIN-Registers bei Erwachsenen unter Immuncheckpoint-Inhibitoren; Phänotypen, Schweregrad, Therapie und Outcomes wurden erfasst.

Ergebnisse

Bis 1. Januar 2026 waren 60 Patient:innen eingeschlossen. Häufigster Phänotyp war eine rheumatoid-arthritis-ähnliche Polyarthritis (41,7 %); 90 % waren moderat oder schwer. 85,0 % erhielten systemische Glukokortikoide, 53,3 % brauchten Zweitlinientherapie.

Schlussfolgerung der Autor:innen

Rheumatische irAEs in einer rheumatologisch zugewiesenen Population waren schwerer als zuvor beschrieben, mit häufiger Eskalation über Glukokortikoide hinaus und oft dauerhaftem Absetzen der Immuncheckpoint-Inhibitoren. Männliches Geschlecht war mit Eskalation assoziiert.

Kernaussagen

  • Häufigster Phänotyp: rheumatoid-arthritis-ähnliche Polyarthritis
  • 90 % moderat oder schwer; 23,3 % Hospitalisierung
  • 53,3 % benötigten Zweitlinientherapie

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift ACR Open Rheumatology, online erschienen am 08.09.2026. Verfasst von Didzis Gailis und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology and Clinical Immunology, Department of Medicine IV, Ludwig-Maximilians-Universität (LMU) University Hospital, LMU Munich, Mu…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

Auf einen BlickAbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Immune checkpoint inhibitors (ICIs) induce a broad range of immune‐related adverse events (irAEs), including rheumatic manifestations. Evidence from dedicated rheumatology cohorts on the clinical spectrum, severity, treatment, and outcomes of rheumatic irAEs (rh‐irAEs) remains limited. We aimed to describe clinical phenotypes, treatment, and outcomes of rh‐irAEs in a national registry.

Methods

The German ERIN Registry (Registry for the Documentation of Rheumatic Immunotherapy‐Related Adverse Events) is a multicenter observational registry of adults receiving ICIs. Rh‐irAEs were classified using a rheumatology‐oriented phenotype‐based framework. Variables included demographics, oncological characteristics, treatments, and outcomes. Severity was graded by Common Terminology Criteria for Adverse Events version 5.0. Univariate analyses identified predictors of second‐line systemic therapy.

Results

As of January 1, 2026, 60 patients (56.7% men; median age 66 years) were included. Predominant malignancy was melanoma (40.0%). The leading phenotype was rheumatoid arthritis‐like polyarthritis (41.7%), followed by polymyalgia rheumatica‐like (18.3%) and peripheral spondyloarthritis‐like syndrome (11.7%). Axial spondyloarthritis (axSpA)–like syndrome occurred in younger patients. Rh‐irAEs were moderate or severe in 90%; 23.3% required hospitalization and 38.3% led to permanent ICI discontinuation. Systemic glucocorticoids (GCs) were used in 85.0%; 58.3% were GC‐refractory and 53.3% required second‐line immunomodulatory therapy. Complete remission was achieved in 33.3% and partial remission in 51.7%. Oncological progression occurred in 15.0% overall and in 28.1% of patients requiring second‐line therapy. Male sex was the strongest predictor of second‐line systemic therapy.

Conclusion

Rh‐irAEs in a rheumatologists‐referred population were more severe than previously described, with frequent ICI discontinuation and escalation beyond GCs. Male sex was associated with treatment escalation. An underrecognized axSpA‐like phenotype occurred in younger patients, warranting further study. image

Autor:innen und Institutionen

  • Division of Rheumatology and Clinical Immunology, Department of Medicine IV, Ludwig-Maximilians-Universität (LMU) University Hospital, LMU Munich, Munich, Germany.
  • Department of Rheumatology and Clinical Immunology, University Hospital Würzburg, Würzburg, Germany.
  • Department of Rheumatology and Clinical Immunology, University Hospital Münster, Münster, Germany.
  • Department of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
  • Rheumazentrum Ruhrgebiet, Herne, Germany.
  • Rheumatology Private Practice, Cologne, Germany.

ORCID-Profile: Didzis Gailis, Fabian T H Ullrich, Marc Schmalzing, Rebecca Hasseli-Fräbel, Uta Kiltz, Karolina Gente, Hendrik Schulze-Koops

Zitieren

APA

Gailis, D., Ullrich, F. T. H., Dombret, S., Schmalzing, M., Hasseli-Fräbel, R., Witte, T., Thiele, T., Kiltz, U., Oleszowsky, M., Müller, M., Gente, K., Specker, C., Thaler, M. B., Skapenko, A., & Schulze-Koops, H. (2026). Clinical Phenotypes, Treatment, and Outcomes of Rheumatic Immune–Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitors: A Rheumatologists‐Referred Multicenter German Registry Cohort. ACR Open Rheumatology, 8(9). https://doi.org/10.1002/acr2.90145

Vancouver

Gailis D, Ullrich FTH, Dombret S, Schmalzing M, Hasseli-Fräbel R, Witte T, et al. Clinical Phenotypes, Treatment, and Outcomes of Rheumatic Immune–Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitors: A Rheumatologists‐Referred Multicenter German Registry Cohort. ACR Open Rheumatology. 2026;8(9). doi:10.1002/acr2.90145

BibTeX
@article{Gailis2026,
  author = {Gailis, Didzis and Ullrich, Fabian T H and Dombret, Sophia and Schmalzing, Marc and Hasseli-Fräbel, Rebecca and Witte, Torsten and Thiele, Thea and Kiltz, Uta and Oleszowsky, Mara and Müller, Marcel and Gente, Karolina and Specker, Christof and Thaler, Matthias B and Skapenko, Alla and Schulze-Koops, Hendrik},
  title = {Clinical Phenotypes, Treatment, and Outcomes of Rheumatic Immune–Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitors: A Rheumatologists‐Referred Multicenter German Registry Cohort},
  journal = {ACR Open Rheumatology},
  year = {2026},
  volume = {8},
  number = {9},
  doi = {10.1002/acr2.90145}
}
Kostenlos starten →